Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Stress Reaction

    Current Location

    Search
    Stress Reaction
    Show Map
    Map View
    Your Location

    Popular Searches

    By Condition

    Depression Clinical Trials

    Anxiety Clinical Trials

    Schizophrenia Clinical Trials

    ADHD Clinical Trials

    Bipolar Disorder Clinical Trials

    Multiple Sclerosis Clinical Trials

    Autism Clinical Trials

    Treatment Resistant Depression Clinical Trials

    Borderline Personality Disorder Clinical Trials

    Social Anxiety Disorder Clinical Trials

    Parkinson's Disease Clinical Trials

    Alzheimer's Disease Clinical Trials

    By Location

    Clinical Trials in California

    Clinical Trials in Florida

    Clinical Trials in Texas

    Clinical Trials in New York

    Clinical Trials in Ohio

    Clinical Trials in Illinois

    Clinical Trials in Pennsylvania

    Clinical Trials in Michigan

    Clinical Trials in North Carolina

    Clinical Trials in Massachusetts

    Clinical Trials in Missouri

    Clinical Trials in Minnesota

    Other People Viewed

    By Subject

    Top Clinical Trials near Bangor, ME

    Top Clinical Trials near Maine

    Top Diabetes Clinical Trials near Seattle, WA

    Top Clinical Trials near Florence, AL

    Top Clinical Trials near Chalmette, LA

    Top Huntington's Disease Clinical Trials

    Top Clinical Trials near Bardstown, KY

    Top Clinical Trials near Anderson, SC

    Top Cirrhosis Clinical Trials

    Top Clinical Trials near Uniondale, NY

    Top Anemia Clinical Trials

    Top Clinical Trials near Burlington, VT

    By Trial

    Niraparib + Abiraterone Acetate + Prednisone for Prostate Cancer

    Avelumab + Talazoparib/Axitinib for Endometrial Cancer

    Tirzepatide + Mibavademab for Obesity

    Cardiac MRI for Breast Cancer

    Chemotherapy + Bevacizumab for Abdominal Cancer

    Therapy and Peer Support for Opioid Use Disorder

    Fecal Microbiota Transplant for Parkinson's Disease

    Multi-agent Chemotherapy + Olaparib and Pembrolizumab for Pancreatic Cancer

    hu14.18-IL2 + Nivolumab + Ipilimumab + Radiation for Melanoma

    Tranexamic Acid for Osteoarthritis

    Endoscopic Ultrasound for Gastrointestinal Cancer

    BI 1356225 for Opioid Use Disorder

    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      61 Stress Reaction Trials Near You

      Power is an online platform that helps thousands of Stress Reaction patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      iCOVER for Acute Stress Disorder

      Detroit, Michigan
      The iCOVER intervention was developed to rapidly restore functioning in individuals experiencing an Acute Stress Reaction (ASR). iCOVER is undergoing widespread adoption but has not been tested for efficacy. iCOVER was designed to be administered by peers, paraprofessionals, or medical personnel in 60-120 seconds, including in military operational environments. The term iCOVER is an acronym that summarizes the six specific steps of the intervention: (1) identify that an individual is experiencing an ASR; (2) Connect with the individual through word, eye contact, and physical touch to draw them back to the present moment; (3) Offer commitment so that the individual feels less psychologically isolated and withdrawn (e.g., "I'm right here with you"); (4) Verify facts - ask simple fact-based questions to engage the individual in deliberate cognitive activity; (5) Establish order of events - briefly review what has happened, what is happening, and what will happen to orient the individual; and (6) Request action to re-engage the individual in purposeful behavior. Participants will be randomly assigned to one of three groups: iCOVER, usual care, or physical presence with reassurance. Investigators have elected to use two different control conditions, in order to examine the reliability of the iCOVER intervention in comparison with two typical responses to individuals experiencing an ASR (i.e., physical presence with reassurance, no specific treatment).
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:18 - 50

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Psychosis, Bipolar, Drug Intoxication, Others

      450 Participants Needed

      Racial Discrimination and Stress Response

      Bowling Green, Kentucky
      The goal of this study is to learn about whether ethnic minority adolescents' racial discrimination experience is related to dysregulated biological responses to subtle racism, and how the relationship may be attenuated or exacerbated by a set of social and cognitive factors. The main questions it aims to answer are: * to reveal the relationship between racial discrimination experiences and ethnic minority adolescents' stress response to subtle racism * to test parental ethnic-racial socialization, children's attribution to subtle racism and their racial identity as potential risk and protective factors.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:9 - 69

      Key Eligibility Criteria

      Disqualifiers:Severe Depression, Severe Anxiety, Others

      160 Participants Needed

      Art Therapy for PTSD in Military Service Members

      Bethesda, Maryland
      This trial studies how art therapy can help military personnel manage their emotions and reduce symptoms of stress and trauma. Participants will attend several sessions, including art therapy sessions to observe changes in emotional regulation. Art therapy has been explored as a treatment for PTSD in military personnel, showing potential benefits in emotional regulation and communication.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:18 - 64

      Key Eligibility Criteria

      Disqualifiers:Brain Injury, Psychotic Disorder, Bipolar, Stroke, Others

      25 Participants Needed

      Propranolol + Hydrocortisone + Morphine for Fear Response

      Silver Spring, Maryland
      This clinical trial aims to evaluate the nature and duration of effects of three FDA-approved medications (propranolol, hydrocortisone, and morphine) on military-relevant cognitive, emotional, and motor performance following an exposure to a stressful situation (i.e., exposure to a tarantula) in physically healthy adult volunteers (aged 18 - 40) with fear of spiders to help the future development of medications for treating Acute Stress Reactions. The main questions this study aims to answer are: Will placebo treatment (oral placebo) result in significant decrements in Psychomotor Vigilance Task (PVT) performance compared to propranolol treatment? Will placebo treatment \[intramuscular (IM) placebo\] result in significant decrements in PVT performance compared to hydrocortisone treatment? Will placebo treatment (IM placebo) result in significant decrements in PVT performance compared to morphine treatment? Participants will receive one of five study medications (oral propranolol, oral placebo, IM hydrocortisone, IM morphine, or IM morphine) after a brief exposure to a tarantula. Participants will complete cognitive and simple motor tasks and psychological assessments before and after the study medication administration.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4
      Age:18 - 40

      Key Eligibility Criteria

      Disqualifiers:Neurologic Disorder, Cardiovascular Disease, Asthma, Others
      Must Not Be Taking:Antipsychotics, Anticonvulsants, Mood Stabilizers, Others

      110 Participants Needed

      MDMA-Assisted Therapy for Post-Traumatic Stress Disorder

      New York, New York
      The purpose of this study is to assess the safety and efficacy of MDMA-Assisted Therapy on Health Care Workers suffering from symptoms of Post-Traumatic Stress due to their work on the frontline of the COVID Pandemic.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Psychotic Disorder, Bipolar I, Others
      Must Not Be Taking:QT Prolonging Drugs

      30 Participants Needed

      Simulated Emergency Department Stress for Stress Management

      Little Rock, Arkansas
      Stress is important for health. As emergency departments (EDs) are often stressful places, a better understanding of the human stress response is important for understanding how and why patients respond as they do when they come to the ED. Since the investigators cannot take up space in the ED for research, the investigators will instead recruit 20 methamphetamine-using participants who are not currently in treatment and 10 healthy adult matched participants to a simulated ED room in the University of Arkansas for Medical Sciences (UAMS) Simulation Center. The investigators will have participants perform a stressor task involving public speaking and a simple arithmetic task. The investigators will see if this experiment can be made to be like being in an actual ED by varying what participants speak about in the task. By doing this, the investigators hope to find out several important things: 1) Is a stressor task feasible and acceptable to participants? 2) What does the stress response -- as measured by cortisol and alpha-amylase -- look like in these participants? 3) Does varying what participants talk about make the experiment seem more like an actual ED? 4) Do participants under stress show even mild symptoms of agitation as measured by clinical scales? If so, how often?
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:21 - 55

      Key Eligibility Criteria

      Disqualifiers:Cardiovascular, Endocrine, Neurologic, Others
      Must Not Be Taking:Daily Medication

      30 Participants Needed

      Probiotics for Autism and Stress in Children

      Davie, Florida
      Using a metabolomics approach in combination with eye-tracking data, this research study proposes to gather evidence from two interrelated body systems (gut and brain) in order to assess how the microbiome is involved in stress modulated symptoms in children with autism and children exposed to repeated stress in comparison to a control group.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:4 - 95

      Key Eligibility Criteria

      Disqualifiers:Severe Cognitive Impairment, Others
      Must Be Taking:Children's Probiotics

      75 Participants Needed

      PROSOMNIA Sleep Therapy for Chronic Insomnia

      Hollywood, Florida
      This clinical trial aims to evaluate the safety and efficacy of PROSOMNIA Sleep Therapy (PSTx) for individuals suffering from chronic insomnia, sleep deprivation, and REM sleep disorders. Chronic insomnia, characterized by difficulty falling or staying asleep, significantly affects patients and quality of life, mood, and cognitive function. REM sleep disorders, in which the body struggles to enter or maintain restful REM sleep, can worsen these issues. The trial introduces a novel therapy using anesthesia-induced sleep, targeting sleep homeostasis and improving sleep architecture. Objectives: The primary goals of the trial are to determine: 1. Whether PROSOMNIA Sleep Therapy increases the quality of REM sleep. 2. Whether PSTx increases the duration of REM and/or NREM sleep. 3. Whether PSTx decreases the time it takes participants to fall asleep (sleep onset latency). Participants will receive ONE (1) PROSOMNIA Sleep Therapy session lasting between 60-120 minutes. Each session uses Diprivan/Propofol to induce sleep, and is monitored via an EEG to ensure proper sleep stages, particularly REM sleep. Participant Criteria: Inclusion: Adults aged 18-65 with diagnosed or undiagnosed chronic insomnia or sleep deprivation. Exclusion: Patients with severe obesity, significant cardiovascular, neurological, or psychiatric conditions, or those with an ASA status above II. Study Design: This trial is non-randomized, single-arm and open-label, with all participants receiving the PSTx. The trial does not include a comparison group, as the focus is on evaluating the immediate, direct effects of the therapy. Participants will undergo continuous EEG monitoring during therapy sessions, allowing researchers to track brain activity and sleep stages in real-time. This method ensures that sleep cycles, particularly REM sleep, are optimized for therapeutic benefit. Therapy Methodology: PROSOMNIA Sleep Therapy leverages anesthesia to mimic natural sleep patterns and enhance the efficiency of REM sleep. Diprivan/Propofol is used to induce REM sleep, while EEG monitoring tracks and maintains proper sleep architecture throughout the session. The therapy promotes the clearance of adenosine, a compound that builds up during wakefulness and drives the need for sleep. Adenosine is cleared during REM sleep, reducing sleep pressure and improving cognitive function. Outcome Measures: Primary Outcomes: Researchers will measure the increase in REM sleep duration, improvement in sleep quality (via self-reported questionnaires), and a reduction in sleep onset latency. Secondary Outcomes: These include changes in mood, cognitive function, and blood serum uric acid levels. Patient-reported outcomes will also be tracked through tools like the PROSOMNIA Sleep Quiz, which is specifically designed for PSTx. Significance: Chronic insomnia and REM sleep disorders affect millions globally, leading to cognitive impairment, mood disturbances, and poor overall health. Traditional treatments, including pharmacological approaches and Cognitive Behavioral Therapy for Insomnia (CBT-I), often provide suboptimal results for many individuals. PSTx offers a novel, therapeutic approach to restoring sleep balance and enhancing the overall quality of sleep, particularly for those who have not responded to conventional treatments. Study Process: Recruitment and Baseline Assessments: Participants undergo a comprehensive sleep assessment, including sleep questionnaires and polysomnography, to establish a baseline for sleep quality and duration. Blood serum uric acid levels will also be measured to track any biochemical changes due to therapy. Therapy Sessions: Only one (1) PROSOMNIA Sleep Therapy session will be administered, with the session lasting between 60-120 minutes. Diprivan/Propofol is used to induce sleep, and EEG will monitor brain activity to ensure the proper balance of sleep stages. Post-Therapy Follow-up: Follow-up assessments will occur at 24 hours, 7 days, and 30 days post-treatment. Researchers will analyze the therapy effects on REM sleep, mood, cognitive function, and other health indicators. Potential Implications: If successful, this trial could revolutionize how we treat sleep disorders by targeting the underlying mechanisms of sleep pressure and REM sleep disruption. PROSOMNIA Sleep Therapy may offer a safe, effective, and immediate alternative for patients who have exhausted other treatment options. Key Concepts: Homeostatic sleep drive, (Process S), caused by adenosine buildup during wakefulness, is disrupted by chronic insomnia. This impacts cognitive function health and recovery. Anesthesia-induced REM sleep via PSTx helps regulate this homeostatic sleep stage, offering deeper and more restorative sleep compared to other sleep therapies. The study uses statistical methods like ANOVA and Chi-square to measure outcomes.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 1
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Severe Obesity, Cardiovascular, Neurological, Others
      Must Not Be Taking:Sedatives, Hypnotics

      100 Participants Needed

      Self-Management Training for Stress Reaction After ICD Shock

      Seattle, Washington
      This study, "Biobehavioral Intervention to Reduce PTSD Symptoms After an ICD Shock," addresses a critical need in cardiology care by describing the feasibility and acceptability of a timely, highly promising, electronically-delivered intervention for patients who have recently received an ICD delivered shock. The study intervention and outcomes are designed to reduce anxiety, enhance return to activities of daily living (ADLs), and prevent the development of severe distress and post-traumatic stress disorder (PTSD), and ultimately promote quality of life. The study is a two-arm, embedded mixed methods, randomized trial (N=60, 30/group). The purpose is to determine feasibility and potential effects of a self-management intervention (SPSM) plus usual care (UC) compared to UC alone, delivered during the critical 1 month period after an ICD shock when distress is high. The intervention will be delivered over 1 month following an ICD shock; a 6-month follow-up will be used to assess the sustainability of intervention effects and determine if the incidence of PTSD is reduced. SPSM includes: 1) training in heart rate (HR) self-monitoring; and 2) individualized learning through 4 self-paced, web-based modules. The study interventions are delivered at a crucial time, closely after an ICD shock when stress is high, but PTSD has not yet developed. The specific aims are to: 1) examine the effects of the SPSM intervention plus UC vs. UC alone on the primary outcome of ICD shock anxiety at 1 and 6 months post-shock event, 2) describe the impact of SPSM plus UC compared to UC alone on the secondary outcomes of total daily physical activity, depression, PTSD symptoms, QOL, salivary cortisol levels, and self-efficacy and outcome expectations at 1 and 6 months post-shock event, and 3) assess feasibility, acceptability, and safety of the SPSM intervention, SDOH will be used to describe differential responses to the SPSM intervention. This study fills a significant gap in the care of patients with an ICD, through the systematic testing of a brief, novel and cost-effective intervention that provides the knowledge and skills to improve quality of life. Study findings will be used to design future larger RCTs to test intervention effectiveness for more diverse samples and settings.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:PTSD, Schizophrenia, Bipolar, Cognitive Dysfunction, Others

      60 Participants Needed

      Nature Walks for Stress Management

      San Francisco, California
      The investigators will test the efficacy of our proposed intervention to reduce embodied stress in four racial/ethnic groups (Black, Latinx, Pilipinx, and Pacific Islander) as a preventative intervention for health disparities found in these communities. The intervention is comprised of two phases. The first consists of community nature walks in a pristine redwood forest for six months. This is followed by chosen nature activities with family and/or friends for three months. The investigators will test the ability of these activities in nature to reduce chronic stress that underpins many health disparities using validated biological, behavioral, and sociocultural measures. The use of these measures is in alignment with the National Institute of Minority Health and Health Disparities (NIMHD) Research Framework, and will increase understanding of individual, interpersonal, community, and social level factors that lead to, and that can eliminate health disparities.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Prisoners, Cognitive Impairment

      200 Participants Needed

      Mind-Body Training for Mild Cognitive Impairment

      Columbus, Ohio
      The goal of this study is to conduct a Stage I pilot study examining the feasibility, acceptability, and preliminary effects of an internet-based, asynchronous mindfulness-based stress reduction program (iMBSR) compared to an internet-based, asynchronous lifestyle education program (iLifeEd), for adults at-risk for Alzheimer's disease (AD). Sixty middle-aged and older adults (aged 50 years or older) with subjective cognitive decline will be randomized to either an 8-week iMBSR program or an 8-week iLifeEd program control group, designed to provide adequate control for placebo effects. Behavioral, neuroimaging, and ecological momentary assessment (EMA) measures of mind-wandering will be administered to determine preliminary effects as a function of engagement in the iMBSR program. AD biomarkers will be examined at pre-training and post-training assessments.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:50+

      Key Eligibility Criteria

      Disqualifiers:Neurological Disorders, Psychotic, Substance Abuse, Others
      Must Not Be Taking:Brain Activity Altering

      60 Participants Needed

      SUI-100 Device for Stress Urinary Incontinence

      Middleburg Heights, Ohio
      The goal of this pivotal clinical trial is to evaluate the safety and effectiveness of the SUI-100 device for the treatment of mild-to-moderate stress urinary incontinence (SUI) in females aged 22-70 years. The main questions this study aims to answer are: 1. Does treatment with the SUI-100 device reduce SUI symptoms, as measured by urine leakage. 2. Is the device safe and effective compared to the sham group? Participants will: 1. Be randomly assigned to an active or sham control group in a blinded, multicenter study. 2. Attend treatment visits during the Treatment Phase, with SUI assessments conducted at specific intervals. 3. Enter a 3-month, treatment-free follow-up phase, with SUI assessment. 4. Proceed to three monthly maintenance treatments, followed by a final SUI assessment at study exit. The total study duration will last approximately 18 months, with each individual's participation lasting approximately 6-8 months. This study aims to provide robust data on the effectiveness, safety, and durability of the SUI-100 device for treating female Stress Urinary Incontinence.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:22 - 77
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:BMI >35, Non-ambulatory, Pregnancy, Others

      130 Participants Needed

      Written Exposure Therapy for PTSD

      Lexington, Kentucky
      Posttraumatic stress disorder (PTSD) is associated with increased rates of prescription opioid misuse, high-risk opioid use, illicit use of substances, and overdose (Meshberg-Cohen et al., 2021) Some research has demonstrated that among individuals with opioid use disorder (OUD), 92% report exposure to a traumatic event (Mills et al., 2005). Approximately 41% of those with OUD have a lifetime history of PTSD and 33.2% of individuals with OUD meet current diagnostic criteria for PTSD, indicating very high rates of PTSD among people with co-occurring OUD (Mills et al., 2006, 2007). PTSD also prospectively increases risk for OUD after exposure to opioids (Hassan et al., 2017). Medications for opioid use disorder (MOUD) are evidence-based pharmacological interventions for OUD (methadone, buprenorphine, naltrexone) to manage pain and withdrawal (Leshner \& Mancher, 2019). Though effective, dropout from MOUD programs is high (Mokri et al., 2016; O'Connor et al., 2020). It is also common in substance use disorder (SUD) treatment settings not to treat PTSD (Norman \& Hien, 2020), though concurrent PTSD and MOUD treatment is associated with higher continuation in MOUD programs compared to no PTSD treatment (Meshberg-Cohen et al., 2019; Schacht et al., 2017). Despite this, there is little data regarding efficacy or effectiveness of specific trauma-focused PTSD treatments among patients in MOUD programs. Combined with effective cognitive-behavioral techniques for substance use disorder (SUD), evaluation of brief, trauma-focused interventions for PTSD has substantial potential to improve care for individuals with PTSD receiving MOUD. The present study will begin to address this need by evaluating the feasibility, acceptability, and initial efficacy of Written Exposure Therapy (WET) for PTSD integrated with harm reduction skills for managing SUD symptoms among a sample of patients receiving MOUD \[Written Exposure Therapy-Integrated (WET-I)\]. WET is a five-session treatment for PTSD requiring limited therapist training and minimal patient burden (Sloan \& Marx, 2019). WET has shown comparable outcomes to gold-standard interventions for PTSD, with improved retention rates (Sloan et al., 2018). WET has marked potential within this population, especially given that many clinicians in SUD programs do not have specialized training in PTSD treatments (Killeen et al., 2015). Using a multiple baseline single case experimental design (SCED), 6 participants with current PTSD and current or past OUD will be recruited from MOUD treatment programs to engage in 5 weekly sessions of WET-I. Participants will complete an intake assessment to establish PTSD and OUD diagnoses and will be randomized to a 3- or 5-week baseline assessment period. Weekly assessments of symptoms (i.e., PTSD, anxiety, depression), substance craving and use, quality of life, and compliance with MOUD treatment will be completed during the baseline, treatment, and one-month follow-up phase. During the treatment phase, participants will also complete weekly measures of therapeutic alliance and will provide feedback on treatment credibility and treatment satisfaction. Aim 1: To examine feasibility and acceptability of WET-I among participants in MOUD treatment with co-occurring PTSD/OUD. Feasibility of WET-I will be demonstrated via treatment retention and completion. Acceptability of engaging in WET-I in tandem with MOUD treatment will be demonstrated via high patient credibility ratings of WET-I and high treatment satisfaction ratings. Aim 2: To determine if WET-I can significantly reduce symptoms of PTSD, anxiety, and depression in participants with comorbid PTSD and OUD and to monitor changes in drug use behaviors and craving over the treatment period. Participants will report reliable clinical improvement in symptoms (PTSD, anxiety, depression) and quality of life during the treatment phase and post-assessment without corresponding increases in substance use behavior or craving, and these improvements will be maintained at follow-up.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      20 Participants Needed

      Family Acceptance Project for Relationship or Family Issues

      Ann Arbor, Michigan
      Research shows that sexual and gender minority youth (SGMY) experience high rates of mental health problems and other challenges (e.g., social, academic). A major factor that leads to these challenges is family rejection (family behaviors and reactions that minimize, deny, ridicule and attempt to prevent or change a child's sexual orientation, gender identity and gender expression). Racial and ethnic minority youth experience the highest rates of family rejection and related health risks. The Family Acceptance Project (FAP) is a research, education, and intervention initiative that was founded more than 20 years ago to help diverse families learn to support and affirm their SGMY. FAP's Family Support Model is grounded in the lived experiences of diverse SGMY and families and uses a culture-based family support framework that enables parents and caregivers to change rejecting behaviors that FAP's research has shown contribute to health risks and increase supportive and accepting behaviors that promote well-being for SGMY. The overall goal of this research project is to evaluate a nine-week online version of FAP's Family Support Model (FAP-O). The investigators will specifically study how FAP-O: 1. Promotes parent/caregiver acceptance and support of their sexual and gender minority youth. 2. Increases family bonding and communication. 3. Increases SGMYs' feelings of pride in being LGBTQ+ and more hopeful about the future. 4. Leads to reductions in mental health problems reported by SGMY who experience family rejection. Before receiving FAP-O's family support services, racial and ethnic minority SGMY (ages 14 to 20) and their caregivers will complete an initial pre-test survey. After completing this initial (baseline) survey, half of the families will participate in program sessions. Following the first round of sessions, all participants will complete an immediate follow-up survey, with an additional survey conducted six months after this. These surveys help us learn if FAP-O impacts the project's goals above. After the final survey, the other half of the families will attend program sessions. The investigators will also ask SGMY and caregivers to share what they liked about the program and their guidance for enhancing it.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:14+

      Key Eligibility Criteria

      Disqualifiers:High-risk Suicide, Active Psychosis, Others

      180 Participants Needed

      H-HOPE Intervention for Premature Infants

      Chicago, Illinois
      This trial tests the H-HOPE program, which helps preterm infants develop through sensory stimulation and supports parents in interacting with their babies. The study aims to see if H-HOPE can be successfully used in different NICUs and if it improves infant health and reduces costs. The results could lead to widespread use of H-HOPE in hospitals. H-HOPE is a standardized behavioral intervention with an infant-directed component designed to optimize developmental trajectories and increase parents' interactive engagement with their infants.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      4600 Participants Needed

      CEDARS Intervention for Stress Relief

      Chicago, Illinois
      Using an adapted stress-reduction intervention called the CEDARS, the investigators will pilot the intervention in adolescents (N=40) to determine the feasibility and acceptability of CEDARS implementation and to investigate adolescent stress reduction. As an exploratory aim, the investigators will explore the influence of the CEDARS on CMH-related behaviors and CMH. The investigators expect that those adolescents who undergo the intervention will have the greatest improvement in mental health symptoms than their waitlisted counterparts. Our secondary hypothesis is that those who report more adversity will also report greater improvement in mental health symptoms than their peers.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:14 - 19

      Key Eligibility Criteria

      Disqualifiers:Age, Language, Internet Access

      40 Participants Needed

      Curcumin for Renal Transplant Health

      Chicago, Illinois
      The primary goal of this study is to investigate if curcumin is beneficial for kidney transplant recipients, a population with extensive baseline vascular dysfunction and cognitive impairment who have few treatment options. The possible mechanisms by which curcumin improves vascular function will be evaluated as well as whether curcumin improves cognitive function in these patients.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Multi-organ Transplant, Pre-transplant Curcumin

      14 Participants Needed

      Peer-led Support Program for Refugee Families

      Chicago, Illinois
      The proposed study draws on prior research to evaluate the feasibility, acceptability and explore preliminary effectiveness of Coffee and Family Education and Support, Version (CAFES2) using a pilot randomized type 1 hybrid effectiveness-implementation design. CAFES2 is a peer-led family and social strengthening multiple family group intervention that is designed to respond to multi-level needs of refugee families. Results of the trial will contribute to the emerging evidence base on family-based mental health interventions for refugee and newcomer communities. The trial will also generate new insights regarding implementation strategies needed to promote successful delivery of services by peer providers and the unique role of human-centered design practices for adaptation of mental health and psychosocial interventions.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:12 - 55

      Key Eligibility Criteria

      Disqualifiers:Developmental Disabilities, Severe Mental Health, Others

      74 Participants Needed

      BTL-699-2 for Sleep Quality

      Minooka, Illinois
      The goal of this clinical trial is to evaluate whether the treatment with BTL-699-2 device is able to improve sleep quality and reduce stress in adults above the age of 22 years. The main questions it aims to answer are: Does the treatment with BTL-699-2 device improve sleep quality? Does the treatment with BTL-699-2 device reduce stress? Participants will be asked to: * Undergo six treatments * Complete the Pittsburgh Sleep Quality Index * Complete the Perceived Stress Scale Questionnaire * Complete the Sleep and Stress Assessment Questionnaire * Complete the Therapy Comfort and Subject Satisfaction Questionnaire

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:22+

      Key Eligibility Criteria

      Disqualifiers:Seizures, Heart Disorders, Tumors, Others
      Must Not Be Taking:Prescription Sleep Meds

      60 Participants Needed

      Cereset for Dementia Caregiver Stress

      Winston-Salem, North Carolina
      This trial tests if Cereset, a sound-based brain therapy, can help caregivers of people with dementia who are stressed or anxious. The therapy aims to improve how their heart responds to stress by balancing brain activity.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Hearing Impairment, Seizure Disorder, Suicidal Thoughts, Others
      Must Not Be Taking:Beta Blockers, Opiates, Antidepressants, Others

      20 Participants Needed

      Why Other Patients Applied

      "I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

      ID
      Pancreatic Cancer PatientAge: 40

      "As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

      IZ
      Healthy Volunteer PatientAge: 38

      "I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

      FF
      ADHD PatientAge: 31

      "I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

      AG
      Paralysis PatientAge: 50

      "I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

      WR
      Obesity PatientAge: 58
      Match to a Stress Reaction Trial

      MDMA-Assisted Psychotherapy for PTSD

      Toronto, Ontario
      This study aims to evaluate the safety, feasibility, acceptability, and effectiveness of MDMA-assisted Cognitive-Behavioral Conjoint Therapy (CBCT) versus CBCT alone for the treatment of Post-Traumatic Stress Disorder (PTSD). PTSD is a debilitating condition that significantly impacts interpersonal relationships and the functioning of individuals and their loved ones. There is also a well-established reciprocal relationship between interpersonal relationships, PTSD, and recovery. CBCT is a manualized treatment for PTSD that simultaneously addresses PTSD symptoms and relationship satisfaction. It provides dyads with behavioral tools to navigate PTSD-related challenges, as well as the knowledge behind PTSD and how it impacts relationships. Previous research has demonstrated the efficacy of CBCT in improving PTSD symptoms, partner functioning, and relationship satisfaction in both distressed and non-distressed dyads. MDMA is a drug commonly used recreationally that has been increasingly studied because of its ability to reduce the impact of PTSD symptoms. The effects of MDMA are reduced fear, enhanced communication, trust and introspection, and increased empathy and compassion. The effects of MDMA create a state that enhances the positive effects of therapy by increasing the ability to tolerate negative emotions and allowing clients to stay engaged in therapy without being overwhelmed by the intense emotions surrounding the memories of traumatic events. It is believed that MDMA may help promote the effects of CBCT due to its ability to induce empathy and interpersonal openness. This randomized study is the second study designed to explore the efficacy of combining MDMA-assisted therapy with CBCT. This study will enroll 30 dyads, where one individual has symptoms of PTSD. Participants will undergo a 7-week psychotherapy course, in MDMA-assisted CBCT or CBCT alone. In the MDMA-assisted CBCT, participants will go through CBCT sessions, and two doses of MDMA will be used as an adjunct to psychotherapy. Participants assigned to the CBCT-only condition will go through CBCT sessions and will have the opportunity to crossover and receive the two MDMA sessions after follow-up. The primary goal of this research is to contribute to the literature on MDMA-assisted CBCT by investigating its feasibility, safety, acceptability, and effectiveness, and by comparing it to active PTSD treatments.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Psychotic Disorders, Heart Disease, Others
      Must Not Be Taking:Psychiatric Medications, Ketamine, Ecstasy, Others

      60 Participants Needed

      Genetic Research for Inherited Eye Diseases

      Bethesda, Maryland
      Background: Adrenocortical carcinoma (ACC) is a rare cancer of the adrenal glands. ACC often returns after tumors are removed with surgery. Less than 35% of people with ACC survive 5 years after diagnosis. Objective: To test a new type of external beam RT before surgery in people with ACC. Eligibility: People aged 18 years and older with ACC that came back after treatment but may be safely removed with surgery. Design: Participants will be screened. They will have a physical exam with blood and urine tests. They will have tests of their heart function. They will have imaging scans. A small sample of tumor tissue may be collected if one is not available. They will undergo laparoscopy: Small incisions will be made in the abdomen so that a thin tube with a light and camera can be inserted to view the organs. RT comes from a machine that aims radiation at tumors. Participants will receive preoperative RT in daily fractions over approximately 2-3 weeks, followed by a planned surgical resection about 4 weeks after the completion of RT. Visits will last 30 to 60 minutes. Participants will undergo surgery to remove their tumors about 4 weeks after they finish RT. They will stay in the hospital 1 to 3 weeks after surgery. Participants will have follow-up visits for 10 years after surgery.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Prior Radiation, Infection, Uncontrolled Diabetes, Others
      Must Not Be Taking:Chemotherapy, Immunotherapy, Investigational Therapies

      32 Participants Needed

      Mindfulness App for Stress Relief

      Baltimore, Maryland
      African American caregivers of people living with HIV/AIDS (PLWHA) have unique needs because they are more likely to experience stressors related to intersecting sources of stigma, discrimination, and caregiving burdens specifically associated with caregiving for PLWHA. The proposed project will enhance and finalize Phase I app development and evaluate its effectiveness in a randomized controlled trial. The project has high public health significance because of its potential to provide an accessible, easy to use mindfulness-based support tool for African American caregivers that could reduce stress, mitigate the harm of intersecting stigmas, and strengthen the caregiver-care recipient relationship.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Inability To Provide Informed Consent

      100 Participants Needed

      Sudarshan Kriya Yoga for Burnout

      Lancaster, Pennsylvania
      This is a prospective, randomized, controlled clinical trial in which clinicians from University of Pennsylvania Health Systems (UPHS) including Penn Medicine- Lancaster General Health (LGH) and Massachusetts General Hospital (MGH) are offered a well-known program to help reduce clinician burnout: Sudarshan Kriya Yoga (SKY) Breathing and Sahaj Meditation Intervention.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:25 - 70

      Key Eligibility Criteria

      Disqualifiers:Atrial Fibrillation, Sleep Apnea, COPD, Others

      180 Participants Needed

      Vagus Auricular Stimulation for Tinnitus

      Saint Louis, Missouri
      This pilot study is a randomized, double-blinded controlled trial of adult participants with chronic, moderate to severe bothersome subjective tinnitus. Participants will be randomly assigned to either an active auricular stimulation device group or a sham-control group.Both groups will also undergo virtual Mindfulness-Based Stress Reduction(MBSR) over 8 weeks to promote tinnitus bother reduction, and general well-being. Outcome measures will be assessed at baseline, end of intervention, and at 1-month post-intervention.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Age >70, Pregnancy, Ear Pathology, Others

      40 Participants Needed

      SKY Breath Meditation for Mental Health

      San Diego, California
      The goal of this pilot SKY (Sudarshan Kriya Yoga) Breath Meditation study is to establish feasibility and acceptability of the intervention; and investigate preliminary effectiveness of the intervention at the DNA methylation, RNA and protein levels in blood samples collected from participants before and after the 8 week SKY intervention. Primary outcomes also include preliminary effectiveness at the physiological level using a wearable device used for continuous monitoring. Secondary outcome measures include behavioral inventories.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Age:21 - 99

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      45 Participants Needed

      Wild Blueberries for High Blood Pressure

      Atlanta, Georgia
      The purpose of the study is to determine the effectiveness of wild blueberries on cardiovascular health, cognitive function, and gut microbiota composition in non-Hispanic Black and White adults with elevated blood pressure.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:45 - 65

      Key Eligibility Criteria

      Disqualifiers:Cancer, Cardiovascular, Neurological, Others
      Must Not Be Taking:Insulin, Antibiotics, Anti-inflammatories, Others

      80 Participants Needed

      Blueberries for Prediabetes

      Atlanta, Georgia
      The goal of this clinical trial is to determine the effectiveness of using a freeze-dried wild blueberry powder on cardiometabolic health, cognitive function, and gut microbiota composition in adult women with prediabetes.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:45 - 65
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Allergies To Berries, Cancer, Hypertension, Smoking, Others
      Must Not Be Taking:Insulin, Antidiabetics, Antibiotics, Anti-inflammatories

      30 Participants Needed

      Parenting Program for Stress in Children

      Chapel Hill, South Carolina
      Purpose: The purpose of this research is to determine the effects of Attachment and Biobehavioral Catch-up (ABC), an evidence-based parenting program, on stress biomarkers in children. Participants: The study will involve approximately 150 caregiver-child dyads, with children aged between 24 and 42 months. Participants will include primary caregivers fluent in English or Spanish, along with their children who have experienced social risk factors for adversity. Procedures (Methods): Participants will be randomly assigned to either receive the ABC parenting program (10 sessions) immediately or be placed on a wait-list, receiving the program after about 4 months. The study procedures include caregivers completing online surveys, engaging in play-based observational tasks with their children, and collecting non-invasive biological samples (saliva, cheek swab, hair) from the children and saliva samples from the caregivers at 2-3 time-points.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Genetic Disorders, Cerebral Palsy, Others
      Must Not Be Taking:Steroids

      150 Participants Needed

      CARE Program for Postpartum Mental Health

      The Bronx, New York
      This trial is testing a group therapy program called CARE for parents with postpartum depression or anxiety. The program helps parents understand their own and their baby's thoughts and feelings to improve mental health and reduce stress. The study targets parents with infants aged 3 to 12 months who are receiving care at Montefiore Medical Center.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Psychosis, Mania, Severe Cognitive Impairment, Others

      21 Participants Needed

      123

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do Stress Reaction clinical trials pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Stress Reaction clinical trials work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Stress Reaction trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Stress Reaction is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Stress Reaction medical study?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Stress Reaction clinical trials?

      Most recently, we added MDMA-Assisted Therapy for Post-Traumatic Stress Disorder, Mindfulness for Binge Drinking and Genetic Research for Inherited Eye Diseases to the Power online platform.